Socrates E. Papapoulos

Research interests

Publications

• 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

  The Lancet Diabetes & Endocrinology · 2017 · https://doi.org/10.1016/s2213-8587(17)30138-9

• The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study

  Osteoporosis International · 2015 · https://doi.org/10.1007/s00198-015-3234-7

• The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension

  The Journal of Clinical Endocrinology & Metabolism · 2013 · https://doi.org/10.1210/jc.2013-1597

• Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research

  Journal of Bone and Mineral Research · 2013 · https://doi.org/10.1002/jbmr.1998

• Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension

  Journal of Bone and Mineral Research · 2011 · https://doi.org/10.1002/jbmr.1479

• Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

  Journal of Bone and Mineral Research · 2010 · https://doi.org/10.1002/jbmr.253

• Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

  Bone · 2008 · https://doi.org/10.1016/j.bone.2008.01.003

• Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

  The FASEB Journal · 2005 · https://doi.org/10.1096/fj.05-4221fje

• SOST/sclerostin, an osteocyte-derived negative regulator of bone formation

  Cytokine & Growth Factor Reviews · 2005 · https://doi.org/10.1016/j.cytogfr.2005.02.005

• Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist

  The Journal of Experimental Medicine · 2004 · https://doi.org/10.1084/jem.20031454

• Bone Morphogenetic Proteins Stimulate Angiogenesis through Osteoblast-Derived Vascular Endothelial Growth Factor A

  Endocrinology · 2002 · https://doi.org/10.1210/endo.143.4.8719

• A New Approach to the Development of Assessment Guidelines for Osteoporosis

  Osteoporosis International · 2002 · https://doi.org/10.1007/s001980200069

• Expression of Vascular Endothelial Growth Factors and Their Receptors during Osteoblast Differentiation

  Endocrinology · 2000 · https://doi.org/10.1210/endo.141.5.7458

• Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis

  Osteoporosis International · 1999 · https://doi.org/10.1007/s001980050224

• Farnesyl Pyrophosphate Synthase Is the Molecular Target of Nitrogen-Containing Bisphosphonates

  Biochemical and Biophysical Research Communications · 1999 · https://doi.org/10.1006/bbrc.1999.1499

• Familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Effects of mutant gene dosage on phenotype.

  Journal of Clinical Investigation · 1994 · https://doi.org/10.1172/jci117062

• Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: A possible role of interleukin-6 in osteoclastogenesis

  Biochemical and Biophysical Research Communications · 1989 · https://doi.org/10.1016/0006-291x(89)90851-6

Current projects

No projects listed.